Research programme: norovirus vaccine - Daiichi Sankyo/UMN Pharma
Latest Information Update: 19 Feb 2014
At a glance
- Originator Daiichi Sankyo Company; UMN Pharma
- Class Virus-like particle vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Norovirus infections